Reuters logo
2 个月前
BRIEF-Fibrocell completes dosing of first cohort in phase 1/2 clinical trial of FCX-007 gene therapy
2017年6月8日 / 中午12点24分 / 2 个月前

BRIEF-Fibrocell completes dosing of first cohort in phase 1/2 clinical trial of FCX-007 gene therapy

June 8 (Reuters) - Fibrocell Science Inc

* Fibrocell completes dosing of first cohort in phase 1/2 clinical trial of FCX-007 gene therapy for treatment of recessive dystrophic epidermolysis bullosa

* No product-related adverse events were reported

* 12-week post-treatment data for safety, mechanism of action and efficacy for multiple patients in phase 1 portion of trial expected in Q3 of 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below